Elsevier

European Journal of Cancer

Volume 44, Issue 13, September 2008, Pages 1904-1913
European Journal of Cancer

VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis

https://doi.org/10.1016/j.ejca.2008.06.031Get rights and content

Abstract

Angiogenesis is crucial for the progression of colorectal carcinomas in which the bioavailability of Vascular Endothelial Growth Factor (VEGF) plays a major role. VEGF bioavailability is regulated by proteolytic release or cleavage. In colorectal cancer patients, we observed a significant correlation between circulating VEGF and tumour tissue Matrix Metalloproteinase-9 (MMP-9) levels but not with MMP-2. Therefore, we evaluated the role of MMP-9 in regulating VEGF bioavailability and subsequent angiogenesis in 3-dimensional human cell culture models. MMP-9 treatment released VEGF dose-dependently from HT29 colon carcinoma spheroids, comparable to heparitinase, a known mediator of VEGF release. Conditioned medium from human neutrophils, containing high amounts of active MMP-9, released VEGF comparable to recombinant MMP-9, in contrast to myofibroblast medium. MMP-9 treated spheroids showed decreased extracellular levels of heparan sulphates, required for VEGF binding to the matrix, whereas the levels in the medium were increased. Western blot analysis revealed that VEGF165 is the major isoform released by MMP-9 treatment. In vitro experiments indicated that MMP-9 is not capable to cleave VEGF165 into smaller isoforms, like plasmin does. These data suggested that MMP-9 mediates release rather than the cleavage of larger VEGF isoforms. Medium from MMP-9 treated HT29 spheroids induced endothelial cell sprouting in an angiogenesis assay, comparable to the effect of recombinant VEGF165. Anti-VEGF antibody treatment resulted in a strongly reduced number of sprouts. In conclusion, we have shown that neutrophil-derived MMP-9 is able to release biologically active VEGF165 from the ECM of colon cancer cells by the cleavage of heparan sulphates.

Introduction

Colorectal carcinomas (CRC) are characterised by enhanced VEGF expression and the corresponding high microvascular densities, indicating increased angiogenic activity and leading to worse patient survival.1, 2 Therapy using anti-VEGF antibodies improves CRC patient survival, emphasising VEGF as a major angiogenic factor.3, 4, 5, 6 VEGF expression is up-regulated by hypoxia and various tumour-related cytokines including Transforming Growth Factor-β, Interleukin-1β, Platelet-derived Growth Factor and Epidermal Growth Factor.7, 8 At least six human VEGF isoforms are known, ranging in length from 121 to 206 amino acids, from which VEGF165 is the most predominant. Except for VEGF121 all isoforms contain a heparin-binding domain mediating adhesion to the extracellular matrix (ECM) by interaction with heparan sulphate proteoglycans (HSPGs).9 Binding of larger isoforms to the ECM provides a reservoir of biologically active VEGF. Consequently, the local release of soluble VEGF is a key factor in angiogenesis. Various proteinases have been studied as mediators of VEGF cleavage and/or release, including members of the matrix metalloproteinase (MMP) family like MMP-2,10, 11 MMP-7,12 MMP-913 and MMP-14.14, 15 Most of the experiments showing the involvement of proteinases in VEGF-release were done using animal models and simple in vitro systems. Because interspecies differences have been described for several substrate/MMP combinations,16 we investigated the role of the gelatinases MMP-2 and MMP-9 in VEGF-bioavailability in human CRC. First, the concentration and localisation of VEGF, MMP-2 and MMP-9 were determined in tissues and plasma of CRC patients. Next, we used a 3-dimensional ECM-producing human colon cancer model system to evaluate the role of several MMPs in VEGF release. Recombinant MMPs and conditioned media from neutrophils and myofibroblasts, cell-types associated with the angiogenic switch, were evaluated for their MMP content and VEGF-releasing capacity. VEGF functionality was determined in a 3-dimensional human endothelial cell sprouting assay, resembling in vivo angiogenesis. This study shows the importance of especially MMP-9 in the release of biologically active VEGF165 from the ECM, mainly by the cleavage of HSPGs, leading to the angiogenic switch in CRC.

Section snippets

Patient material

Pre-operative plasma and tissue specimens from 46 patients (29 ♂, 17 ♀) undergoing resection for primary CRC at the department of Oncologic Surgery, Leiden University Medical Centre, were collected as described before.17 Tissues were homogenised in Tris/Tween-80 and the protein concentrations were determined as described previously.18, 19 For immunohistochemistry, tissue specimens were fixed in 4% paraformaldehyde, dehydrated in graded alcohol and xylene and embedded in paraffin. All human

VEGF and MMP-2 and -9 levels in CRC and in the circulation

Fig. 1 shows the concentrations of VEGF and MMP-9 in CRC and the corresponding mucosa. VEGF and MMP-9 levels were significantly enhanced in tumours (both P < 0.0001, n = 46 pairs) and were mutually correlated (R = 0.405, P < 0.0005, n = 92). Tissue MMP-2 levels were not enhanced in CRC compared to normal mucosa (18.4 versus 18.3 ng/mg protein, n = 46 pairs) and did not correlate with the tumour VEGF concentration. Tumour levels of MMP-2 and MMP-9 correlated weakly with each other (R = 0.250, P = 0.019), but

Discussion

The ability of VEGF to induce angiogenesis depends on the presence of active, mobile isoforms within the microenvironment. After production and release from the cells, VEGF bioavailability is regulated via cleavage and/or release by proteolytic activity in combination with the acidic pH present in the tumour microenvironment.26 heparanases,27, 28 plasmin,9, 29 urokinase,30, 31 phoshatidyl-inositol phosholipase C9 and MMPs11, 12, 13, 14, 15 have been shown to cleave larger VEGF isoforms into

Conflict of interest statement

None declared.

Acknowledgements

We thank Mrs. C. Coomans from the Centre for Human Genetics (Leuven University, Belgium) for providing the HSPG antibody, Dr. I.M. Teepe-Twiss (Department of Clinical Pharmacy and Toxicology, LUMC) for providing Bevacuzimab, E. Dreef, Dr. A. Gorter and Prof Dr. P.C.W. Hogendoorn (Department of Pathology, LUMC) for immunohistochemical support and J.M. van der Zon (Department of Gastroenterology-Hepatology, LUMC) for excellent technical assistance.

References (42)

  • J. Plouët et al.

    Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect

    J Biol Chem

    (1997)
  • N. Ortega et al.

    Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix

    Biol Cell

    (1998)
  • K. Werther et al.

    Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma (The Danish RANX05 Colorectal Cancer Study Group)

    Eur J Surg Oncol

    (2000)
  • G. Hashimoto et al.

    Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165

    J Biol Chem

    (2002)
  • F.J. Kubben et al.

    Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer

    Eur J Cancer

    (2007)
  • P. Parsons-Wingerter et al.

    A VEGF(165)-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity

    Microvasc Res

    (2006)
  • S. Zheng et al.

    Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma

    World J Gastroenterol

    (2003)
  • G. Des Guetz et al.

    Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature

    Br J Cancer

    (2006)
  • R.S. Kerbel

    Tumor angiogenesis: past, present and the near future

    Carcinogenesis

    (2000)
  • P. Carmeliet

    VEGF as a key mediator of angiogenesis in cancer

    Oncology

    (2005)
  • N. Ferrara et al.

    Targeting VEGF-A to treat cancer and age-related macular degeneration

    Annu Rev Med

    (2007)
  • Cited by (0)

    1

    These authors contributed equally to the work.

    View full text